Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-08-01

Clinical Trial Update: Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating dexamethasone to reduce everolimus-induced oral stomatitis in cancer patients was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • DEXAMETHASONE (Dexamethasone)
  • Everolimus (everolimus)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Malignant Neoplasm | Phase 3 | Status: TERMINATED | Results posted: 2022-08-01